Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167811 | 0.89 | CA2 (0.56) | LTA4HCA2PPARAFFAR1 | |
| SCHEMBL77492 | 0.87 | CA2 (0.59) | MAOBCA2TAAR1IGF1RALOX15 | |
| Ethylene Glycol SCHEMBL11585117 | 0.84 | MAOA (0.58) | LTA4HMAOBMAOACA2S1PR5 | |
| SCHEMBL20591074 | 0.83 | LTA4H (0.65) | LTA4HEPHX2MAOBMAOAS1PR5 | |
| SCHEMBL17787256 | 0.83 | LTA4H (0.65) | LTA4HCA2PPARAPPARGFFAR1 | |
| SCHEMBL11003085 | 0.82 | MAOB (0.50) | LTA4HMAOBMAOATAAR1PPARA | |
| SCHEMBL966309 | 0.82 | MAOB (0.69) | LTA4HEPHX2MAOBMAOA | |
| SCHEMBL28309115 | 0.82 | CA2 (0.54) | MAOBCA2TAAR1IGF1RALOX15 | |
| SCHEMBL5312844 | 0.82 | LMNA (0.60) | LTA4HEPHX2PPARAPPARGFFAR1 | |
| SCHEMBL16755611 | 0.81 | LTA4H (0.69) | LTA4HEPHX2CA2PPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590321-B1 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1590321-A2 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067498-A2 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | LTA4H 540/4885EPHX2 1065/4885MAOB 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.